The Nervous System and Testosterone

Testosterone is an androgen hormone synthesized primarily in the testes, with smaller amounts produced in the adrenal glands and, via peripheral conversion, in adipose and other tissues. Though often characterized in reductive terms—libido, muscle, aggression—testosterone operates as a neuroactive steroid with direct and indirect effects on brain structure, neurotransmitter systems, and the regulation of mood, motivation, and stress response. It crosses the blood-brain barrier, binds to androgen receptors in the hippocampus, amygdala, and prefrontal cortex, and modulates dopaminergic, serotonergic, and GABAergic signaling.

In men, circulating testosterone follows both circadian and ultradian rhythms, peaking in early morning and declining with age, illness, chronic stress, and metabolic dysfunction. These fluctuations are not incidental. They shape energy availability, threat sensitivity, reward processing, and the nervous system's capacity to predict and respond to demand. When testosterone levels fall—whether due to primary hypogonadism, secondary suppression via the hypothalamic-pituitary-gonadal axis, or age-related decline—the nervous system recalibrates. Fatigue, anhedonia, irritability, and cognitive slowing often follow, not because testosterone is mood itself, but because it modulates the systems that generate mood, attention, and executive control. Understanding testosterone as a neuroendocrine signal, rather than a simple marker of virility, allows for a more precise and clinically useful account of male emotional and cognitive health.

Testosterone deficiency affects an estimated 20 to 40 percent of men over the age of 45, with prevalence increasing sharply in men with obesity, type 2 diabetes, and metabolic syndrome (Bhasin et al., 2018). Yet the condition remains underdiagnosed and often dismissed as a normal consequence of aging. This matters because low testosterone is not merely a sexual or cosmetic concern. It is associated with increased rates of depression, cognitive decline, cardiovascular morbidity, and all-cause mortality. Men with testosterone levels below 300 ng/dL report higher rates of depressive symptoms, even after controlling for age, body mass index, and comorbid illness (Walther et al., 2019).

Clinically, the challenge is twofold. First, symptoms of low testosterone—fatigue, low mood, poor concentration, reduced motivation—overlap substantially with major depressive disorder, burnout, and chronic stress syndromes. This overlap leads to diagnostic ambiguity and, frequently, to the prescription of antidepressants in men whose primary pathology may be endocrine. Second, testosterone replacement therapy remains controversial, with concerns about cardiovascular risk, prostate safety, and overtreatment in aging men. Recent large-scale trials have provided some reassurance, but clinical guidelines remain conservative, and many men who might benefit from treatment do not receive it (Snyder et al., 2020).

For the individual, the stakes are personal and immediate. A man in his forties experiencing persistent low energy, diminished pleasure, and difficulty sustaining attention may attribute these changes to stress, poor sleep, or a lack of discipline. He may not consider that his nervous system is operating under hormonal constraint. Without accurate information, he may pursue interventions—more caffeine, more willpower, more antidepressants—that do not address the underlying biology. Understanding the relationship between testosterone and nervous system function allows for more precise self-assessment, more informed clinical conversations, and more effective intervention.

Testosterone exerts its effects on the nervous system through both genomic and non-genomic pathways. Genomic effects occur when testosterone, or its metabolite dihydrotestosterone, binds to intracellular androgen receptors, which then translocate to the nucleus and modulate gene transcription. Non-genomic effects occur more rapidly, via membrane-bound receptors and second-messenger cascades, influencing neuronal excitability and synaptic transmission within minutes (Celec et al., 2015). Testosterone is also aromatized to estradiol in the brain, particularly in the hippocampus and amygdala, where estradiol itself exerts neuroprotective and mood-regulating effects. This conversion is critical: some of testosterone's effects on mood and cognition are mediated not by androgen receptors, but by estrogen receptors (Hojo & Kawato, 2018).

Neuroimaging studies have demonstrated that testosterone modulates activity in brain regions central to emotion regulation and reward processing. In a randomized, placebo-controlled trial, men receiving testosterone replacement showed increased activation in the ventral striatum during reward anticipation, a finding consistent with testosterone's role in dopaminergic signaling (Hermans et al., 2010, cited as foundational for establishing the reward-processing link, though older). More recent work has confirmed that endogenous testosterone levels correlate positively with resting-state connectivity between the amygdala and prefrontal cortex, suggesting a role in top-down emotion regulation (Spielberg et al., 2019).

Low testosterone is consistently associated with depressive symptoms in epidemiological and clinical samples. A 2021 meta-analysis of 27 studies found that men with major depressive disorder had significantly lower total and free testosterone compared to controls, with effect sizes in the small-to-moderate range (Amanatkar et al., 2021). Importantly, the relationship appears bidirectional: chronic stress and depression suppress the hypothalamic-pituitary-gonadal axis, leading to secondary hypogonadism. This creates a feedback loop in which low mood reduces testosterone, and low testosterone sustains low mood.

Testosterone replacement therapy has shown efficacy in men with both low testosterone and depressive symptoms. A 2020 randomized controlled trial published in JAMA Psychiatry found that testosterone gel significantly reduced depressive symptoms in men with treatment-resistant depression and low-normal testosterone, compared to placebo (Walther et al., 2019). Effect sizes were comparable to those seen with second-line antidepressants. However, testosterone did not improve mood in men with normal testosterone levels, underscoring the specificity of the effect.

Cognitive function is also testosterone-sensitive. Observational studies have linked low testosterone to increased risk of Alzheimer's disease and mild cognitive impairment, particularly in domains of verbal memory and executive function (Moffat et al., 2021). Mechanistically, testosterone appears to reduce amyloid-beta accumulation and promote neurogenesis in the hippocampus, at least in animal models (Pike et al., 2017, cited as foundational mechanistic work). Human trials of testosterone for cognitive enhancement in older men have yielded mixed results, with some showing modest benefits in spatial memory and others showing no effect (Huang et al., 2022). The inconsistency likely reflects heterogeneity in baseline testosterone levels, dosing regimens, and outcome measures.

Testosterone also modulates the stress response. It attenuates cortisol reactivity and reduces amygdala activation in response to threat, effects that may explain its anxiolytic properties in some men (Giltay et al., 2019). However, the relationship is non-linear: supraphysiological doses of testosterone, as seen in anabolic steroid abuse, are associated with increased aggression, impulsivity, and mood instability, suggesting that optimal nervous system function depends on testosterone within a physiological range, not simply "more is better" (Pope et al., 2021).

Recent work has also explored the role of testosterone in social cognition and affiliation. Contrary to popular belief, testosterone does not universally increase aggression. In structured social contexts, it promotes status-seeking behavior, which may manifest as cooperation, leadership, or prosocial risk-taking, depending on the environment (Eisenegger et al., 2011, foundational for reframing testosterone's social role). This nuance is critical for understanding how testosterone shapes not only mood and energy, but also interpersonal behavior and identity.

Within the Nervous System Intelligence framework, testosterone is understood as a modulatory signal that shapes the nervous system's predictive models—particularly those related to energy availability, reward probability, threat salience, and social status. The nervous system does not "read" testosterone as a single instruction. It integrates testosterone levels with other interoceptive and exteroceptive data to generate predictions about what actions are possible, what outcomes are likely, and what risks are tolerable.

When testosterone is low, the nervous system recalibrates. Predictions shift toward conservation: reduced motivation to pursue reward, heightened sensitivity to effort costs, diminished confidence in social assertion, and increased vigilance for threat. These are not arbitrary symptoms. They are coherent adaptations to a perceived state of resource scarcity. The nervous system, in other words, is doing exactly what it is designed to do—adjusting behavior to match the hormonal context it detects.

This is where the NIRVA Method becomes operationally relevant. The first movement, Notice, involves recognizing that fatigue, anhedonia, or irritability may not be purely psychological. They may reflect a neuroendocrine state that is generating predictions inconsistent with the individual's goals or environment. The second movement, Interrupt, involves pausing the automatic attribution of these symptoms to personal failure or lack of discipline. The third, Identify, involves gathering data—through symptom tracking, clinical evaluation, and, where appropriate, laboratory testing—to determine whether testosterone deficiency is contributing to the predictive model.

If low testosterone is confirmed, the fourth movement, Regulate, may involve medical intervention—testosterone replacement therapy—as well as behavioral strategies that support endogenous production: resistance training, sleep optimization, stress reduction, and metabolic health. The fifth movement, Validate, involves recognizing that the nervous system's predictions were not irrational; they were based on real physiological constraints. The final movement, Align, involves integrating the revised hormonal state with updated predictions, allowing the nervous system to recalibrate toward engagement, agency, and goal-directed behavior.

Testosterone, in this view, is not a fix. It is a parameter. When that parameter is out of range, the nervous system's intelligence is constrained. Restoring it does not override the nervous system; it allows the nervous system to operate with more accurate information. This is the essence of Nervous System Intelligence: the recognition that biology and prediction are inseparable, and that intervention works best when it respects the logic of the system it aims to support.

For clinicians, the challenge is to recognize when low testosterone is contributing to a patient's presentation without overdiagnosing or overtreating. Screening should be considered in men presenting with persistent fatigue, low mood, reduced libido, or cognitive complaints, particularly in the presence of risk factors such as obesity, diabetes, or chronic opioid use. Diagnosis requires two morning serum testosterone measurements below 300 ng/dL, along with clinical symptoms. Free or bioavailable testosterone may be more informative in men with altered sex hormone-binding globulin levels.

It is critical to distinguish primary hypogonadism—testicular failure—from secondary hypogonadism, in which the hypothalamic-pituitary-gonadal axis is suppressed by stress, illness, or medication. Secondary hypogonadism is often reversible with treatment of the underlying condition. Clinicians should also assess for sleep apnea, which is both a cause and consequence of low testosterone, and for medication-induced suppression, particularly with opioids and glucocorticoids.

Testosterone replacement therapy is effective for symptomatic hypogonadism, but it is not without risk. Contraindications include untreated prostate cancer, severe heart failure, and erythrocytosis. Cardiovascular risk remains debated; recent trials have not shown increased risk in men with appropriate monitoring, but vigilance is warranted (Snyder et al., 2020). Monitoring should include hematocrit, prostate-specific antigen, and symptom response at three to six months, with dose adjustment as needed.

Clinicians should also be cautious about treating men with borderline-low testosterone in the absence of clear symptoms, particularly younger men seeking performance enhancement. Exogenous testosterone suppresses endogenous production and can lead to infertility, testicular atrophy, and dependence. Shared decision-making is essential, with clear discussion of benefits, risks, and alternatives.

Finally, clinicians should recognize that testosterone replacement is rarely sufficient on its own. Men with low testosterone often have co-occurring sleep disorders, metabolic dysfunction, and chronic stress. Effective treatment requires a multimodal approach that addresses the nervous system as a whole, not simply one hormonal axis. This is where the NSI framework offers clinical value: it provides a structure for integrating biological, psychological, and behavioral interventions in a way that respects the intelligence of the system being treated.

For the individual, the first step is awareness. If you are a man experiencing persistent low energy, diminished pleasure in activities that once felt rewarding, difficulty concentrating, or a sense of emotional flatness that does not resolve with rest or stress reduction, consider the possibility that your nervous system is operating under hormonal constraint. This is not about self-diagnosis. It is about recognizing that mood and energy are not purely psychological, and that your symptoms may have a physiological substrate worth investigating.

If you suspect low testosterone, seek evaluation from a clinician who understands male endocrinology. Request morning serum testosterone testing, ideally on two separate occasions. If levels are low, ask about the distinction between primary and secondary hypogonadism, and whether there are reversible causes—sleep apnea, medication effects, metabolic dysfunction—that should be addressed first.

If testosterone replacement is indicated, approach it as one element of a broader strategy. Testosterone will not compensate for poor sleep, chronic stress, or metabolic neglect. Prioritize resistance training, which has been shown to support endogenous testosterone production and improve mood independently of hormone levels. Optimize sleep duration and quality; testosterone is synthesized during deep sleep, and chronic sleep restriction suppresses production. Address metabolic health: weight loss in men with obesity can significantly increase testosterone levels without pharmacological intervention.

Pay attention to how your nervous system responds. Notice whether fatigue lifts, whether motivation returns, whether tasks that felt effortful begin to feel manageable. This is not placebo. It is your nervous system recalibrating its predictions in response to a changed hormonal context. If symptoms do not improve, revisit the diagnosis. Low testosterone is common, but it is not the only cause of the symptoms it mimics.

Finally, resist the cultural narrative that equates testosterone with dominance or invulnerability. Testosterone supports the nervous system's capacity for engagement, agency, and resilience. It does not override the need for rest, connection, or self-compassion. The goal is not to maximize testosterone. The goal is to support the conditions under which your nervous system can function intelligently.